カテゴリ： GlobalData, イスラエル, 企業調査

RedHill Biopharma Ltd (RDHL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：RedHill Biopharma Ltd (RDHL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9856
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：132
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes therapeutics in the areas of gastroenterology (GI) and cancer. The company’s commercial product portfolio consists of Donnatal for IBS and acute enterocolitis; Esomeprazole Strontium Delayed-Release Capsules 49.3 mg for GERD and other GI conditions; and EnteraGam, a medical food intended for the dietary management. It sells these three specialty GI products in select US territories. RedHill is investigating pipeline candidates for the treatment of GI disorders and cancer that include helicobacter pylori infection, Crohn’s disease, multiple sclerosis and pancreatic cancer among others. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd (RDHL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 14
Partnerships 15
RedHill Biopharma Enters into Co-Marketing Agreement with Napo Pharma 15
RedHill Biopharma Enters into Agreement with ParaPRO 16
RedHill Biopharma Enters into Research Agreement with Aarhus University 17
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 18
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 19
RedHill Biopharma Enters into Agreement with NIAID 20
RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 21
Licensing Agreements 22
RedHill BioPharma Enters into Licensing Agreement with Entera Health 22
IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 23
Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 24
RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 25
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 27
RedHill Biopharma Enters into Licensing Agreement with Temple University 28
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 29
RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 30
Equity Offering 31
RedHill Biopharma Raises USD25 Million in Public Offering of American Depositary Shares 31
RedHill Biopharma Raises USD22.5 Million in Public Offering of American Depositary Shares 33
RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 35
RedHill Biopharma Withdraws Public Offering of ADSs 37
RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 38
RedHill Biopharma Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of ADSs for USD14.4 Million 40
RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 42
RedHill Biopharma Completes Private Placement Of Shares And Warrants For US$11.7 Million 43
RedHill Biopharma Completes Private Placement Of Units For US$8.5 Million 45
RedHill Biopharma Completes Private Placement Of Shares For US$7 Million 47
RedHill Biopharma Ltd – Key Competitors 49
RedHill Biopharma Ltd – Key Employees 50
RedHill Biopharma Ltd – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Recent Developments 52
Financial Announcements 52
Aug 30, 2018: RedHill Biopharma reports second quarter 2018 financial results and provides update on operations 52
May 08, 2018: RedHill Biopharma Reports First Quarter 2018 Financial Results 55
Feb 22, 2018: RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update 57
Nov 13, 2017: RedHill Biopharma Reports 2017 Third Quarter Financial Results 59
Jul 25, 2017: RedHill Biopharma Reports 2017 Second Quarter Financial Results 62
May 03, 2017: RedHill Biopharma Reports 2017 First Quarter Financial Results 64
Feb 23, 2017: RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results 65
Corporate Communications 67
Jul 23, 2018: RedHill Biopharma announces uplisting to nasdaq global market 67
Jan 04, 2017: RedHill and Concordia sign co-promotion agreement for Donnatal drug promotion 68
Product News 69
04/19/2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D 69
01/12/2017: RedHill Biopharma Provides Milestone Update on YELIVA (ABC294640) 70
01/11/2017: RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections 71
Product Approvals 72
Sep 12, 2018: RedHill Biopharma announces positive end-of-phase II meeting with FDA on BEKINDA for IBS-D 72
Apr 04, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA for the Treatment of Cholangiocarcinoma 73
Clinical Trials 75
Sep 06, 2018: RedHill Biopharma announces advancement to second stage of phase IIa study with YELIVA for Cholangiocarcinoma 75
Sep 04, 2018: RedHill Biopharma announces completion of enrollment for confirmatory phase III study with TALICIA for H. pylori infection 76
Jul 24, 2018: RedHill Biopharma enrolls 400th patient in confirmatory phase III study with TALICIA for H. pylori Infection 77
May 30, 2018: RedHill Biopharma to Present Positive Phase II Results of BEKINDA for IBS-D at Digestive Disease Week 2018 78
May 14, 2018: RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15 79
May 07, 2018: RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease 80
May 04, 2018: RedHill Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA for H. pylori 81
Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting 82
Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D 83
Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D 84
Dec 22, 2017: RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA) for Cholangiocarcinoma at Mayo Clinic and MD Anderson 85
Nov 09, 2017: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease 86
Oct 23, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104 88
Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D 89
Oct 02, 2017: RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018 91
Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017 93
Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of YELIVA in Combination Therapy for Hard-to-Treat Cancers 94
Jul 31, 2017: RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease 95
Jul 17, 2017: RedHill Biopharma Announces Last Patient Visit in BEKINDA Phase II Study for IBS-D 97
Jul 12, 2017: RedHill Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease 98
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 100
Jun 15, 2017: RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA) for H. pylori Infection 101
Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 103
May 04, 2017: RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017 105
Apr 24, 2017: RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D 106
Apr 20, 2017: RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA Phase I Study Results in Advanced Solid Tumors 107
Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA 109
Mar 22, 2017: RedHill Biopharma to Present at the 2017 MAP Conference 110
Mar 21, 2017: RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease 111
Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 112
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 114
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda 116
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-104 117
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-105 118
Jan 10, 2017: RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection 119
Jan 09, 2017: RedHill Biopharmas RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium 121
Jan 06, 2017: RedHill Biopharma Announces YELIVA (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference 122
Jan 04, 2017: RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium 124
Other Significant Developments 125
Apr 09, 2018: RedHill Biopharma Provides Semi-Annual Business Update 125
Dec 05, 2017: RedHill Biopharma Provides 2017 Year-End Business Update 126
Aug 10, 2017: RedHill Biopharma Provides 2017 Semi-Annual Business Update 127
Mar 29, 2017: RedHill Biopharma: Notice of Annual General Meeting of Shareholders 130
Appendix 132
Methodology 132
About GlobalData 132
Contact Us 132
Disclaimer 132

List of Tables
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
RedHill Biopharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 14
RedHill Biopharma Enters into Co-Marketing Agreement with Napo Pharma 15
RedHill Biopharma Enters into Agreement with ParaPRO 16
RedHill Biopharma Enters into Research Agreement with Aarhus University 17
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 18
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 19
RedHill Biopharma Enters into Agreement with NIAID 20
RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 21
RedHill BioPharma Enters into Licensing Agreement with Entera Health 22
IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 23
Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 24
RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 25
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 27
RedHill Biopharma Enters into Licensing Agreement with Temple University 28
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 29
RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 30
RedHill Biopharma Raises USD25 Million in Public Offering of American Depositary Shares 31
RedHill Biopharma Raises USD22.5 Million in Public Offering of American Depositary Shares 33
RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 35
RedHill Biopharma Withdraws Public Offering of ADSs 37
RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 38
RedHill Biopharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD14.4 Million 40
RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 42
RedHill Biopharma Completes Private Placement Of Shares And Warrants For US$11.7 Million 43
RedHill Biopharma Completes Private Placement Of Units For US$8.5 Million 45
RedHill Biopharma Completes Private Placement Of Shares For US$7 Million 47
RedHill Biopharma Ltd, Key Competitors 49
RedHill Biopharma Ltd, Key Employees 50
RedHill Biopharma Ltd, Subsidiaries 51

List of Figures
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[RedHill Biopharma Ltd (RDHL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Colt Technology Services Group Ltd：企業の戦略的SWOT分析
    Colt Technology Services Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • City Holding Co (CHCO)：企業の財務・戦略的SWOT分析
    City Holding Co (CHCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Fortis Inc.：企業の戦略・SWOT・財務分析
    Fortis Inc. - Strategy, SWOT and Corporate Finance Report Summary Fortis Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • EBTEC Corporation：企業の戦略・SWOT・財務情報
    EBTEC Corporation - Strategy, SWOT and Corporate Finance Report Summary EBTEC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Evonik Industries AG：企業のM&A・事業提携・投資動向
    Evonik Industries AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Evonik Industries AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Invictus Oncology Pvt Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Invictus Oncology Pvt Ltd (Invictus Oncology) is a biopharmaceutical company with focus on the discovery, development and commercialization of anti-cancer drugs. The company develops platinum-based drugs to treat various types of cancers. It engineers platinum-based drugs harnessing structur …
  • Perilya Limited：企業の戦略・SWOT・財務情報
    Perilya Limited - Strategy, SWOT and Corporate Finance Report Summary Perilya Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Pendopharm-製薬・医療分野：企業M&A・提携分析
    Summary PendoPharm is a healthcare company that offers production and commercialization of a wide range of drugs. The company’s products comprise spans prescription drugs, over-the-counter and behind-the-counter products. Its prescription products offers drugs for therapeutic areas of gastroenterolo …
  • GN Hearing AS-医療機器分野：企業M&A・提携分析
    Summary GN Hearing A/S (GN Hearing) formerly, GN ReSound A/S, a subsidiary of GN Store Nord A/S is a medical equipment company that provides advanced hearing health care solutions. It manufactures advanced technology hearing instruments and solutions for all types of ear-related problems. The compan …
  • Allahabad Bank (ALBK)：企業の財務・戦略的SWOT分析
    Allahabad Bank (ALBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CIRCOR Aerospace Products Group：企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Clevexel Pharma SAS-製薬・医療分野：企業M&A・提携分析
    Summary Clevexel Pharma SAS (Clevexel) is a drug development company that develops drugs to treat diseases of the central nervous system. The company’s pipeline product portfolio includes CVXL-0107, a glutamate release inhibitor developed to improve the quality of life for Parkinson’s disease patien …
  • Enmax Corporation：電力：M&Aディール及び事業提携情報
    Summary ENMAX Corporation (ENMAX), a subsidiary of City of Calgary, is a vertically integrated energy utility. It generates, transmits and distributes electricity; supplies natural gas; and provides value-added services. Through its subsidiaries, the company undertakes deregulated electricity genera …
  • Electricite de France SA (EDF)：企業の財務・戦略的SWOT分析
    Electricite de France SA (EDF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Essential Energy：企業の戦略的SWOT分析
    Essential Energy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Aclara Technologies LLC-エネルギー分野：企業M&A・提携分析
    Summary Aclara Technologies LLC (Aclara), as a subsidiary of Sun Capital Partners, Inc. The company designs, develops and commercializes Advanced Metering Infrastructure (AMI) solutions for data value management, customer communication and device networking activities. It provides an array of custom …
  • Senetas Corporation Limited：企業の戦略・SWOT・財務情報
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TomTec Imaging Systems GmbH-医療機器分野：企業M&A・提携分析
    Summary TomTec Imaging Systems GmbH (TomTec), formerly TomTec Tomographic Technologies GmbH is a medical device company that offers medical imaging and information management solutions. The company's products comprise image-arena platform, tomtec-arena, reporting, web-solution, IT integration, 2D ec …
  • Pine Cliff Energy Ltd (PNE)：企業の財務・戦略的SWOT分析
    Summary Pine Cliff Energy Ltd (Pine Cliff) is an oil and gas company that offers exploration, production, and development of natural gas, crude oil, and natural gas liquids. The company operates through its core areas such as Edson Assets, Central Assets, and Southern Assets. It acquired Hatton prop …
  • Jcb Co., Ltd.：企業の戦略・SWOT・財務分析
    Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆